Efficacy and safety of the hypoxia-activated prodrug TH-302 in combination with gemcitabine and nab-paclitaxel in human tumor xenograft models of pancreatic cancer
Jessica D. Sun(Threshold Pharmaceuticals (United States)), Charles P. Hart(University of Auckland), Deepthi Bhupathi(University of Auckland), Qian Liu(Southeast University), Yan Wang(Wuhan University), Wen‐Wu Li(VA Palo Alto Health Care System), Ayesha S. Ruprell(Threshold Pharmaceuticals (United States)), Dharmendra Ahluwalia(Threshold Pharmaceuticals (United States)), Fanying Meng(Shanghai University)
Cited by 51
Related Papers
Evolving epidemiology and transmission dynamics of coronavirus disease 2019 outside Hubei province, China: a descriptive and modelling study
|The Lancet Infectious Diseases|2020|720
Molecular and Cellular Pharmacology of the Hypoxia-Activated Prodrug TH-302
|Molecular Cancer Therapeutics|2011|206
DACH1 antagonizes CXCL8 to repress tumorigenesis of lung adenocarcinoma and improve prognosis
|Journal of Hematology & Oncology|2018|125